Biocon Academy records 100% placements

Biocon on July 24, 2014, officially released its Q1 FY15 results. Following which the company hosted an official conference call with media fellows and journalists to further discuss its financial results


Dr Kiran Mazumdar-Shaw, CMD, Biocon

Biocon's CMD Dr Kiran Mazumdar-Shaw, CEO & JMD Dr Arun Chandavarkar, and the newly appointed president, finance & CFO, Mr Siddharth Mittal were present during the call to answer queries from the media.

"Our better mix of products and licensing revenues has enabled us to boost our profits, including the EBITDA this quarter," revealed Dr Kiran Mazumdar.

Biocon is erecting its first overseas biopharma manufacturing and research facility in Johor, Malaysia. The facility is said to be the largest integrated insulin production plant in Asia, built with an investment of US$ 160 million.

Dr Kiran considers Malaysia to be an attractive investment destination. "Investment in Malaysia is attractive for many reasons including tax holidays, availability of higher quality of power and water, and competitive costs, making it an ideal destination. The Malaysian government's support and approval process have been really smooth and we are very pleased with the experience," she appreciated.

According to the company's website, it has already started recruiting professionals for its new Malaysian facility.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email